Researchers at the University of Manchester reported an ATP‑free enzyme‑driven method for nucleotide triphosphate synthesis—an advance the authors argue could lower costs and environmental footprint for oligonucleotide therapeutics manufacturing. The work, published in Nature Communications, targets bottlenecks in NTP supply for large‑scale oligo production. The enzymatic route avoids ATP contamination and simplifies production of modified NTPs used in therapeutic oligos. The team positions the approach as complementary to their prior enzymatic oligo‑assembly methods and as a path to scale sustainable oligo manufacturing. If translated to GMP processes, the method could reduce COGS for RNA and DNA therapeutics and reshape supplier strategies for oligo-dependent programs.